Hot Keywords
non-alcoholic fatty liver disease epidemiology microenvironment nonalcoholic steatohepatitis transplantation cholangiocarcinoma direct-acting antiviral immunotherapy hepatitis B hepatitis C liver resection imaging cancer stem cell diagnosis gene cirrhosis biomarker recurrence

Hepatoma Res 2021;7:[Accepted].10.20517/2394-5079.2021.85@The Author(s) 2021
Accepted Manuscript
Open AccessReview

Adjuvant treatment of hepatocellular carcinoma after resection

Correspondence Address: Prof. Allan Tsung, Division of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, 410 W 10th Ave, N-924 Doan Hall, Columbus, OH 43210, USA. E-mail:


© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (, which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.


Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer and surgical resection offers an opportunity for cure in patients fortunate enough to have tumor amenable to resection. Unfortunately, recurrence rates are as high as 70% 5-year after resection and recurrent disease proves to be a major obstacle to improving prognosis. Many adjuvant treatments have been utilized after resection in hopes of improving survival and have failed. In this review, we outline previous adjuvant strategies for patients with resected HCC and discuss potential steps forward to finding a successful adjuvant therapy.

Cite This Article

Brown ZJ, Tsung A. Adjuvant treatment of hepatocellular carcinoma after resection. Hepatoma Res 2021;7:[Accept].

© 2016-2021 OAE Publishing Inc., except certain content provided by third parties